Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Boundless Bio Inc Is A Clinical-Stage Oncology Company. It Is Focused On Developing Cancer Therapeutics That Address The Unmet Need In Patients With Oncogene-Amplified Tumors By Targeting Extrachromosomal Dna (Ecdna), A Root Cause Of Oncogene Amplification Observed In Cancer Patients. Using Its Proprietary Spyglass Platform, The Company Identifies Targets Essential For Ecdna Functionality, Then Designs And Develops Small-Molecule Drugs Called Ecdna-Directed Therapies (Ecdtx) To Inhibit Those Targets. Its Main Ecdtx Candidate Under Development, Bbi-940, Is A Novel, Oral, Selective Degrader That Has Demonstrated Potent Anti-Tumor Activity Across A Range Of Cancer Cell Lines And Mouse Xenograft Models, Including Single-Agent Tumor Regressions.